CID-103 for purpura

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 3 Jan 2025: Trial started, NCT07017725
  2. 12 Jun 2025: Trial registered, NCT07017725

The trials

NCT07017725: A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia

State
Under way
Phase
Phase 1 and Phase 2
People
75 planned
Started
3 Jan 2025
Primary completion
1 Jun 2026
Arms
Part B (Randomized Dose Exploration) high-dose cohort, Part B (Randomized Dose Exploration) intermediate-dose cohort, Part B (Randomized Dose Exploration) low-dose cohort, Part A (Dose Escalation) Cohort 1- 30 mg/30 mg, Part A (Dose Escalation) Cohort 1- 30 mg/150 mg, Part A (Dose Escalation) Cohort 1- 150 mg/300 mg, Part A (Dose Escalation) Cohort 1- 150 mg/600 mg, Part A (Dose Escalation) Cohort 1- 150 mg/900 mg
Results
None posted
  1. 3 Jan 2025: Trial started
  2. 12 Jun 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.